# Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

> **NCT02437591** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Europe Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Inflammatory Bowel Disease (IBD)
- Clostridium Difficile Infection (CDI)

## Interventions

- **DRUG:** fidaxomicin

## Key facts

- **NCT ID:** NCT02437591
- **Lead sponsor:** Astellas Pharma Europe Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-13
- **Primary completion:** 2016-05-12
- **Final completion:** 2016-10-24
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437591, "Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02437591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*